# Boryung Pharmaceutical Co., Ltd clinical trials: 143 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 143 trials with Boryung Pharmaceutical Co., Ltd as lead sponsor, 23 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Boryung Pharmaceutical Co., Ltd: 143 rows for $7.15, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/boryung-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 143
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 25 newest of 143, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 6, 2026 | NCT07685054 | To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'. | Boryung Pharmaceutical Co., Ltd | Observational | Not yet recruiting | Essential Hypertension, Primary Hypercholesterolemia | 12,700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685054) |
| February 19, 2026 | NCT07421414 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Not yet recruiting | Essential Hypertension | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421414) |
| February 19, 2026 | NCT07421401 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Not yet recruiting | Essential Hypertension | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421401) |
| February 19, 2026 | NCT07421388 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Not yet recruiting | Essential Hypertension | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421388) |
| February 19, 2026 | NCT07421375 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Not yet recruiting | Essential Hypertension | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421375) |
| January 28, 2026 | NCT07373613 | A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | Boryung Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Essential Hypertension | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07373613) |
| December 4, 2025 | NCT07263191 | A Study of Olanzapine in Participants With Bipolar Disorder. | Boryung Pharmaceutical Co., Ltd | Observational | Recruiting | Bipolar Disorder | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263191) |
| December 4, 2025 | NCT07263178 | A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. | Boryung Pharmaceutical Co., Ltd | Observational | Recruiting | Metastatic Colorectal Cancer | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263178) |
| September 18, 2025 | NCT07180771 | A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. | Boryung Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Peripheral T Cell Lymphoma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07180771) |
| July 24, 2025 | NCT07083401 | A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Diabete Mellitus | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083401) |
| July 24, 2025 | NCT07083388 | A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Diabetes Mellitus | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083388) |
| July 16, 2025 | NCT07069335 | A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Ovarian Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07069335) |
| May 15, 2025 | NCT06972732 | A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2... | Boryung Pharmaceutical Co., Ltd | Phase 4 | Recruiting | Type 2 Diabetes | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06972732) |
| March 24, 2025 | NCT06890299 | A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Type 2 Diabetes | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06890299) |
| March 24, 2025 | NCT06890286 | A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Type 2 Diabetes | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06890286) |
| March 21, 2025 | NCT06889064 | A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Essential Hypertension | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06889064) |
| March 21, 2025 | NCT06889012 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Essential Hypertension, Primary Hypercholesterolemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06889012) |
| March 17, 2025 | NCT06879158 | A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Type 2 Diabetes | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06879158) |
| March 17, 2025 | NCT06879132 | A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Type 2 Diabetes | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06879132) |
| March 10, 2025 | NCT06867497 | A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1 | Boryung Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Metastatic Adenocarcinoma of the Pancreas | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06867497) |
| February 12, 2025 | NCT06821945 | A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia | Boryung Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Schizophrenia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06821945) |
| December 20, 2024 | NCT06744439 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Essential Hypertension | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06744439) |
| December 20, 2024 | NCT06744426 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Essential Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06744426) |
| December 20, 2024 | NCT06744127 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Essential Hypertension | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06744127) |
| December 20, 2024 | NCT06744062 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in... | Boryung Pharmaceutical Co., Ltd | Phase 1 | Completed | Essential Hypertension | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06744062) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 77 |
| Phase 2 | 9 |
| Phase 3 | 22 |
| Phase 4 | 6 |
| Observational | 28 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 118 |
| Recruiting | 16 |
| Not yet recruiting | 7 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Essential Hypertension | 43 |
| Hypertension | 40 |
| Diabetes Mellitus, Type 2 | 12 |
| Diabetes Mellitus | 6 |
| Hyperlipidemias | 6 |
| Dyslipidemias | 4 |
| Duodenal Ulcer | 3 |
| Hepatitis | 3 |
| Lymphoma, Follicular | 2 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Encephalitis, Japanese | 2 |
| Smoking Cessation | 2 |
| Ischemic Stroke | 2 |
| Hypercholesterolemia | 2 |
| Breast Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Lymphoma, B-Cell | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Multiple Myeloma | 1 |
| Dermatomycoses | 1 |
| Candidiasis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
- [Home builders in the United States](https://specstream.ai/data/businesses/home-builders/united-states)
- [Sushi restaurants in the United States](https://specstream.ai/data/businesses/sushi-restaurants/united-states)
- [DUI law firms in the United States](https://specstream.ai/data/businesses/dui-law-firms/united-states)
